Stockscreener 앱 받기
8.02
0.12%
0.010
시장 영업 전:
8.24
0.22
+2.74%
전일 마감가:
$8.01
열려 있는:
$7.85
하루 거래량:
1.57M
Relative Volume:
0.69
시가총액:
$1.34B
수익:
-
순이익/손실:
$-174.61M
주가수익비율:
-4.0711
EPS:
-1.97
순현금흐름:
$-165.54M
1주 성능:
-8.76%
1개월 성능:
-12.92%
6개월 성능:
+8.97%
1년 성능:
-28.39%
1일 변동 폭
$7.66
$8.3499
1주일 범위
$7.66
$9.21
52주 변동 폭
$5.9857
$11.84
89 Bio Inc Stock (ETNB) Company Profile
명칭
89 Bio Inc
전화
(415) 432-9270
주소
142 SANSOME STREET, SAN FRANCISCO, CA
ETNB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
8.02 | 1.34B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.28 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.66 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.21 | 34.84B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.92 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-14 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 재개 | BofA Securities | Buy |
| 2024-01-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-08-28 | 개시 | UBS | Buy |
| 2023-06-13 | 개시 | Evercore ISI | Outperform |
| 2022-05-12 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | 개시 | H.C. Wainwright | Buy |
| 2021-10-26 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-19 | 개시 | Raymond James | Strong Buy |
| 2020-09-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-23 | 개시 | BTIG Research | Buy |
| 2020-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2019-12-09 | 개시 | BofA/Merrill | Neutral |
| 2019-12-09 | 개시 | Oppenheimer | Outperform |
| 2019-12-09 | 개시 | RBC Capital Mkts | Outperform |
| 2019-12-09 | 개시 | SVB Leerink | Outperform |
모두보기
89 Bio Inc 주식(ETNB)의 최신 뉴스
Victory Capital Management Inc. Acquires 1,437 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
PNC Financial Services Group Inc. Increases Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Given Sell (D-) Rating at Weiss Ratings - Defense World
89bio, Inc. (NASDAQ:ETNB) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $27.56 Average Target Price from Analysts - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Sold by Steward Partners Investment Advisory LLC - Defense World
89bio (NASDAQ:ETNB) Research Coverage Started at The Goldman Sachs Group - Defense World
Citigroup Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
Goldman Sachs starts 89bio stock with neutral, $11 target By Investing.com - Investing.com Australia
Goldman Sachs Initiates Coverage of 89bio (ETNB) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Goldman Sachs starts 89bio stock with neutral, $11 target - Investing.com India
89bio initiated with a Neutral at Goldman Sachs - TipRanks
Commit To Buy 89bio At $7.50, Earn 25.1% Annualized Using Options - Nasdaq
Citigroup Initiates Coverage of 89bio (ETNB) with Buy Recommendation - Nasdaq
Citigroup Initiates 89bio Inc at Buy With $25 Price Target -March 13, 2025 at 07:13 am EDT - Marketscreener.com
89bio initiated with a Buy at Citi - TipRanks
Time nigh for I&I? Key data points ahead - BioWorld Online
89bio Inc (NASDAQ: ETNB) Is On The Fall - Stocks Register
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings - Defense World
Rhumbline Advisers Has $1.02 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New York State Common Retirement Fund Has $128,000 Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Can 89bio's Liver Disease Pipeline Impress Investors at Upcoming Leerink Conference? - StockTitan
Cantor maintains Overweight on 89bio stock, price target at $29 - Investing.com
Cantor maintains Overweight on 89bio stock, price target at $29 By Investing.com - Investing.com UK
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy - Investing.com
89bio’s (ETNB) “Buy” Rating Reiterated at HC Wainwright - Defense World
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products - MSN
Decoding 89bio Inc (ETNB): A Strategic SWOT Insight - GuruFocus.com
89bio Inc. Advances Clinical Trials Amid Financial Losses - TipRanks
89bio (NASDAQ:ETNB) Stock Price Down 9.1%What's Next? - MarketBeat
89bio (NASDAQ:ETNB) Announces Earnings Results, Misses Estimates By $0.42 EPS - MarketBeat
Cantor Fitzgerald maintains 89bio stock with $29 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains 89bio stock with $29 target - Investing.com
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Globe and Mail
89bio, Inc. SEC 10-K Report - TradingView
89bio Secures $727.5M War Chest While Advancing Critical Phase 3 Trials — What's Next for ETNB? - StockTitan
89bio (ETNB) Projected to Post Earnings on Thursday - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $31.43 Consensus PT from Brokerages - Defense World
Weiss Ratings Reaffirms "Sell (D-)" Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Cell Sorting Market Size to Hit USD 601.89 Million by 2034 - BioSpace
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? - MSN
89bio, Inc. (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Should You Buy 89BIO (ETNB) After Golden Cross? - Nasdaq
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - Defense World
89bio Inc (NASDAQ: ETNB) Is A Buzzing Hot Stock - Stocks Register
89 Bio Inc (ETNB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
89 Bio Inc 주식 (ETNB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McWherter Charles | Director |
Jan 22 '25 |
Buy |
6.71 |
10,000 |
67,100 |
25,000 |
| McWherter Charles | Director |
Jan 21 '25 |
Buy |
6.55 |
5,000 |
32,750 |
15,000 |
| Le-Nguyen Quoc | See Remarks |
Jan 15 '25 |
Sale |
6.49 |
10,963 |
71,150 |
271,833 |
1.87%
0.18%
자본화:
|
볼륨(24시간):